Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research from Lidia Vasilieva's lab in the Department of Biochemistry sheds light on how transcription termination in eukaryotes is controlled.

Binding surfaces of elongation and termination factors on Pol II overlap. Pol II crystal structure with Spt4/5 (PDB ID: 5XON ) (pink) showing mapped positions of lysine-lysine cross-links (turquoise spheres) between Pol II subunits (grey) and termination factor Seb1.

The findings, from Dr Vasilieva's group in collaboration with colleagues in the Department of Chemistry, are published in Cell Reports (1) and demonstrate that conserved mechanisms are used at different steps of transcription. The work will help to fill the gaps in our understanding of how RNA polymerase II is released at the end of transcription.

All three stages of the transcription cycle of mRNAs - initiation, elongation and termination - are tightly regulated. The multi-protein complex RNA polymerase II (Pol II) interacts with a different set of factors to regulate the transition between these stages. The factors modulate how Pol II behaves, changing its ability to interact with DNA, incorporate nucleotides or pause.

Find out more (Department of Biochemistry website)

Similar stories

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Researchers develop machine learning algorithm to diagnose deep vein thrombosis

A team of researchers are developing the use of an artificial intelligence (AI) algorithm with the aim of diagnosing deep vein thrombosis (DVT) more quickly and as effectively as traditional radiologist-interpreted diagnostic scans, potentially cutting down long patient waiting lists and avoiding patients unnecessarily receiving drugs to treat DVT when they don’t have it.

COVID-19 recovery project nominated for HSJ award

The project, involving Oxford University Hospitals, Defence Medical Services (DMS), and the Radcliffe Department of Medicine is in the running for a prestigious honour at the Health Service Journal Awards 2021.